Home > Haematology > EHA 2022 > Caplacizumab is safe and effective in patients with iTTP, also in the long term

Caplacizumab is safe and effective in patients with iTTP, also in the long term

Presented By
Prof. Marie Scully, University College London Hospitals, UK
Conference
EHA 2022
Trial
Phase 3, post-HERCULES
Data from the post-HERCULES trial support the long-term safety and efficacy of caplacizumab, including its repeated use, in patients with acquired or immune-mediated thrombotic thrombocytopenic purpura (iTTP). Acquired or immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare thrombotic microangiopathy that is characterised by thrombocytopenia and haemolytic anaemia. Recently, the HERCULES trial (NCT02553317) showed that among patients with iTTP, treatment with caplacizumab was associated with faster normalisation of the platelet count; with a lower incidence of a composite of iTTP-related death, recurrence of iTTP, or a thromboembolic event during the treatment period; and with a lower rate of recurrence of iTTP during the trial than placebo [1]. However, follow-up in the HERCULES trial was 28 days after the end of treatment. To evaluate the long-te...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on